TAK1 blockade as a therapy for retinal neovascularization

Area of Science:

• Ophthalmology
• Molecular Biology
• Cell Biology

Background:

• Retinal neovascularization is a major cause of blindness.
• Transforming growth factor-β-activated kinase 1 (TAK1) mediates inflammatory signals but its role in retinal neovascularization is unclear.

Purpose of the Study:

• To investigate the role of TAK1 in pathological retinal angiogenesis.
• To explore TAK1 inhibition as a potential therapeutic strategy for retinal neovascular diseases.

Main Methods:

• Utilized TAK1 knockout human endothelial cells and transcriptome analysis.
• Employed a rat model of oxygen-induced retinopathy (OIR).
• Administered pharmacological TAK1 inhibitor (5Z-7-oxozeaenol) in cellular and animal models.

Main Results:

• TAK1 is essential for NFκB signaling activation and downstream gene expression in endothelial cells responding to inflammation.
• TAK1 inhibition attenuated endothelial cell angiogenic activities.
• TAK1-mediated NFκB signaling is enriched in OIR rat retinas and human proliferative diabetic retinopathy neovascular membranes.
• TAK1 inhibition reduced hypoxia-induced inflammation, microglial activation, and aberrant retinal angiogenesis in OIR rats.

Conclusions:

• TAK1 plays a significant role in mediating inflammatory responses that drive pathological retinal angiogenesis.
• Targeting TAK1 with inhibitors like 5Z-7-oxozeaenol demonstrates therapeutic potential for treating retinal neovascularization.